Literature DB >> 20412759

Immunotherapy of type 1 diabetes: where are we and where should we be going?

Xunrong Luo1, Kevan C Herold, Stephen D Miller.   

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic beta cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by "tolerogenic" antigen-presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells, which have demonstrated efficacy in nonobese diabetic (NOD) mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing beta cells from endogenous progenitors. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20412759      PMCID： PMC2860878          DOI： 10.1016/j.immuni.2010.04.002

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  127 in total

1.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

2.  Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

Authors:  Nicole A Sherry; Wei Chen; Jake A Kushner; Mariela Glandt; Qizhi Tang; Sue Tsai; Pere Santamaria; Jeffrey A Bluestone; Anne-Marie B Brillantes; Kevan C Herold
Journal:  Endocrinology       Date:  2007-08-02       Impact factor: 4.736

3.  Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.

Authors:  C L Vanderlugt; K L Neville; K M Nikcevich; T N Eagar; J A Bluestone; S D Miller
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

4.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

5.  Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.

Authors:  Sally C Kent; Yahua Chen; Lisa Bregoli; Sue M Clemmings; Norma Sue Kenyon; Camillo Ricordi; Bernhard J Hering; David A Hafler
Journal:  Nature       Date:  2005-05-12       Impact factor: 49.962

6.  Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

Authors:  Nanette C Schloot; Guido Meierhoff; Csaba Lengyel; Gyözö Vándorfi; József Takács; Pál Pánczél; László Barkai; László Madácsy; Tamás Oroszlán; Peter Kovács; Gábor Sütö; Tadej Battelino; Nora Hosszufalusi; György Jermendy
Journal:  Diabetes Metab Res Rev       Date:  2007-05       Impact factor: 4.876

7.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Authors:  Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell
Journal:  Lancet       Date:  2008-09-22       Impact factor: 79.321

8.  Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer.

Authors:  M J Clare-Salzler; J Brooks; A Chai; K Van Herle; C Anderson
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

10.  CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes.

Authors:  Kristin V Tarbell; Sayuri Yamazaki; Kara Olson; Priscilla Toy; Ralph M Steinman
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307
View more
  62 in total

1.  Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

Authors:  Tatiana Takiishi; Hannelie Korf; Tom L Van Belle; Sofie Robert; Fabio A Grieco; Silvia Caluwaerts; Letizia Galleri; Isabella Spagnuolo; Lothar Steidler; Karolien Van Huynegem; Pieter Demetter; Clive Wasserfall; Mark A Atkinson; Francesco Dotta; Pieter Rottiers; Conny Gysemans; Chantal Mathieu
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

Review 2.  Treg vaccination with a strong-agonistic insulin mimetope.

Authors:  Benno Weigmann; Carolin Daniel
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 3.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

Review 4.  Have we overestimated the benefit of human(ized) antibodies?

Authors:  Daniel R Getts; Meghann T Getts; Derrick P McCarthy; Emily M L Chastain; Stephen D Miller
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

5.  Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Authors:  Suchitra Prasad; Adam P Kohm; Jeffrey S McMahon; Xunrong Luo; Stephen D Miller
Journal:  J Autoimmun       Date:  2012-05-28       Impact factor: 7.094

6.  DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.

Authors:  Gayatri Mukherjee; Ari Geliebter; Jeffrey Babad; Pere Santamaria; David V Serreze; Gordon J Freeman; Kristin V Tarbell; Arlene Sharpe; Teresa P DiLorenzo
Journal:  Int Immunol       Date:  2013-09-10       Impact factor: 4.823

7.  Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.

Authors:  Damien Bresson; Georgia Fousteri; Yulia Manenkova; Michael Croft; Matthias von Herrath
Journal:  J Autoimmun       Date:  2011-11-06       Impact factor: 7.094

Review 8.  Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.

Authors:  Suchitra Prasad; Dan Xu; Stephen D Miller
Journal:  Rev Diabet Stud       Date:  2012-12-28

9.  Regulatory T cells control diabetes without compromising acute anti-viral defense.

Authors:  Carmen Baca Jones; Philippe P Pagni; Georgia Fousteri; Sowbarnika Sachithanantham; Amy Dave; Teresa Rodriguez-Calvo; Jacqueline Miller; Matthias von Herrath
Journal:  Clin Immunol       Date:  2014-05-22       Impact factor: 3.969

Review 10.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.